Company / Revenue per Share
Viridian Therapeutics, Inc.\DE Revenue per Share History
FY2016-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.55
FY2017
5-year range
-
FY2016-FY2017
Trend
-88.7%
vs FY2016
Sector context
#116 of 154
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's revenue per share of $0.55 is lower than 75% of companies in the Health Care sector (FY2017).
Based on SEC 10-K filings.
0.55 in FY2017.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 154This company $0.55 Sector average $15.09
▼
-96.3% below sector average
Key checks
Key Insights
- In FY2017, revenue per share decreased 88.7% year-over-year.
- Ranks #116 out of 154 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $0.55 | -88.7% |
| FY2016 | $4.90 | +225.1% |
As of FY2017 · SEC 10-K · Updated Jun 30, 2026